Company Filing History:
Years Active: 2025
Title: Emma Jane Cummins: Innovator in Cancer Therapy
Introduction
Emma Jane Cummins is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of cancer therapy through her innovative research and development. Her work focuses on the creation of novel therapeutic agents that target specific cancer markers.
Latest Patents
Emma holds a patent for a polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and a method of use thereof to make a radionuclide complex. This patent describes heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies, which are useful for cancer therapy. Her innovative approach has the potential to enhance treatment options for patients suffering from cancer.
Career Highlights
Emma has established herself as a key figure in the biotechnology sector. She is currently associated with Abdera Therapeutics Inc., where she continues to advance her research in antibody development and cancer treatment. Her dedication to innovation has positioned her as a leader in her field.
Collaborations
Emma collaborates with notable professionals in her industry, including Michael J. Abrams and Adam Daniel Judge. These partnerships enhance her research capabilities and contribute to the development of effective cancer therapies.
Conclusion
Emma Jane Cummins is a trailblazer in the field of cancer therapy, with her innovative patent and collaborative efforts paving the way for future advancements. Her work exemplifies the impact of dedicated inventors in the fight against cancer.